EAPI Share Price Performance
€1.31
-1.58 (-54.61%)
54.8% undervalued intrinsic discount
€2.90
Fair Value
Price €1.31
AnalystHighTarget €2.90
AnalystLowTarget €1.00
AnalystConsensusTarget €2.00
Fair Value€2.90
Share Pricen/a
Narrative Update • Jun 16
Euroapi S.A. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 11 Fair Values set on narratives written by author
EAPI Community Narratives
AN
Fair Value
·Fair Value €2.9 54.8% undervalued intrinsic discount
Green Chemistry And Domestic Sourcing Will Unlock Secular Demand
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value €1 31.0% overvalued intrinsic discount
Rising Regulatory And Geopolitical Risks Will Undermine API Profits
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value €2 34.5% undervalued intrinsic discount
Capacity Expansion And Biotechnological Processes Will Strengthen API Supply
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
Rising Regulatory And Geopolitical Risks Will Undermine API Profits
Euroapi makes key ingredients used in many medicines, but growing red tape and a world that’s turning more inward could make it harder to sell profitably across borders. The bigger question is whether its push into more specialized products and efficiency gains can offset pressure from big customers, price wars, and shifting drug technology.Read more
AN
€1
31.0% overvalued intrinsic discount
Fair Value
Profit Margin
0.24%
Future PE
61.68x
Price in 2029
€1.21
Capacity Expansion And Biotechnological Processes Will Strengthen API Supply
Key Takeaways Investments in capacity expansion, innovation, and premium CDMO projects position Euroapi for increased high-value API market share and resilient, higher-margin revenue growth. Structural cost reductions, site divestments, and regionalization trends are expected to strengthen profitability, operating efficiency, and long-term earnings stability.Read more
AN
€2
34.5% undervalued intrinsic discount
Fair Value
Profit Margin
1.72%
Future PE
15.56x
Price in 2029
€2.41
Green Chemistry And Domestic Sourcing Will Unlock Secular Demand
Key Takeaways Aggressive cost-cutting, advanced API technology, and government subsidies position Euroapi for substantial, sustained margin and revenue growth far beyond consensus expectations. Strategic expansion in both European and emerging markets, combined with a focus on high-value clients, strengthens global market share and ensures durable, compounding cash flows.Read more
AN
€2.9
54.8% undervalued intrinsic discount
Fair Value
Profit Margin
3.4%
Future PE
10.14x
Price in 2029
€3.46
Trending Discussion
Recently Updated Narratives
AN
EAPI: Revenue Contraction And Margin Pressure Will Continue To Restrain Future Earnings
Fair Value: €1 31.0% overvalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
EAPI: Lower Expectations On 2026 Outlook Will Support Future Rebound Potential
Fair Value: €2 34.5% undervalued intrinsic discount
6 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
EAPI: Future Cost Controls May Unlock Upside Despite 2026 Sales Headwinds
Fair Value: €2.9 54.8% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Euroapi S.A. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Jul 29, 2026
- -2.22
- 17.00%
- -24.77%
- 5.8%
About EAPI
- Founded
- 2020
- Employees
- 2961
- CEO
- WebsiteView website
Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally. The company offers contract development manufacturing organization for different classes of tides that use solid phase chemistry; particle engineering; microbial fermentation; small molecules synthesis; prostaglandins; and steroids and hormones substances. It also provides API solutions, such as vitamin B12, prostaglandins, corticoids and hormones, anti-infectives, opiates and controlled substances, small and complex molecules, and intermediates and reagents. It sells their products to laboratories in the pharmaceutical industry, manufacturers of generic drug and animal health products, consumer health companies, nutrition companies, cosmetics companies, biotechnology companies, contract development and manufacturing organizations. Euroapi S.A. was incorporated in 2020 and is based in Paris, France.
Recent EAPI News & Updates
Narrative Update • Jun 02
EAPI: Weaker Demand And Margin Pressure Will Drag On Future Earnings
Analysts have cut Euroapi's price target sharply, with recent revisions moving from €2.90 to a range of €1.70 and €1. This reflects more cautious assumptions on revenue trends, margins and a higher P/E multiple applied to the stock.
Narrative Update • May 10
